Scientific publications


Gyllemark et al. 2017. Intrathecal Th17- and B cell-associated cytokine and chemokine responses in relation to clinical outcome in Lyme neuroborreliosis: a large retrospective study. J Neuroinflammation. Feb 1;14(1):27.

Hytönen et al. 2014. CXCL13 and neopterin concentrations cerebrospinal fluid of patients with Lyme neuroborreliosis and other diseases that cause neuroimflammation. J Neuroinflammation. 11:103.

Karrasch M et al. 2017. Neuroborreliosis and acute encephalopathy: The use of CXCL13 as a biomarker in CNS manifestations of Lyme borreliosis. Ticks Tick Borne Dis. Dec 11.

Pietikäinen A et al. 2016. Cerebrospinal fluid cytokines in Lyme neuroborreliosis. J Neuroinflammation. Oct 18;13(1):273.

Pietikäinen A et al. Point-of-care testing for CXCL13 in Lyme neuroborreliosis.
Diagn Microbiol Infect Dis. 2018 Jul;91(3):226-228. doi: 10.1016/j.diagmicrobio.2018.02.013. Epub 2018 Feb 23.

Remy MM et al. 2017. Cerebrospinal fluid CXCL13 as a diagnostic marker of neuroborreliosis in children: a retrospective case-control study. J Neuroinflammation. 14(1): 173.

Rupprecht et al. 2009. The chemokine CXCL13 is a key regulator of B cell recruitment to the cerebrospinal fluid in acute Lyme neuroborreliosis. J Neuroinflammation. 2009 Dec 30;6:42.

Schmidt et al. 2011. A prospective study on the role of CXCL13 in Lyme neuroborreliosis. Neurology. 2011 Mar 22;76(12):1051-8.

Wagner JN. et al. 2018. CXCL13 as a diagnostic marker of neuroborreliosis and other neuroinflammatory disorders in an unselected group of patients. J Neurol. 265: 74 - 81.


Koedel U et al. 2015. Lyme neuroborreliosis -epidemiology, diagnosis and management. Nat Rev Neurol. 2015 Aug;11(8):446-56.